SERPINB3 and metabolic dysfunction-associated steatohepatitis: The close relation between SerpinB3, the levels of HIF-2α and their role in the modulation of the YAP/Myc pathway during carcinogenesis in MASH patients highlights the potential of SerpinB3 as novel therapeutic target.